Biomarkers for clinical decision-making in the management of pulmonary embolism

Clinical Chemistry

Volumn 63, Issue 1, 2017, Pages 91-100

  Giannitsis, Evangelos ^a   Katus, Hugo A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; HEART TYPE FATTY ACID BINDING PROTEIN; MICRORNA; NATRIURETIC FACTOR; TROPONIN; UNCLASSIFIED DRUG;

ALGORITHM; BIOMICS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; EVIDENCE BASED PRACTICE; HUMAN; KIDNEY; LUNG EMBOLISM; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; METABOLISM;

ALGORITHMS; BIOMARKERS; CLINICAL DECISION-MAKING; HUMANS; PULMONARY EMBOLISM;

EID: 85008471363     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.255240     Document Type: Review

References (42)

1. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358:1037-52.
2. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-69.
3. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123:1788-830.
4. Giannitsis E, Mair J, Christersson C, Siegbahn A, Huber K, Jaffe AS, et al. How to use D-dimer in acute cardiovascular care. [Epub ahead of print] Eur Heart J Acute Cardiovasc Care. 2015 Oct. 8. as doi: 10.1177/2048872615610870.
5. Harjola VP, Mebazaa A, Čelutkiené J, Bettex D, Bueno H, Chioncel O, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016;18:226-41.
6. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014;370:1402-11.
7. Elias A, Mallett S, Daoud-Elias M, Poggi JN, Clarke M. Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis. BMJ Open. 2016;6:e010324.
8. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med 2006;166:169-75.
9. Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:1383-89.
10. Lankeit M, Friesen D, Schäfer K, Hasenfuß G, Konstantinides S, Dellas C. A simple score for rapid risk assessment of non-high-risk pulmonary embolism. Clin Res Cardiol 2013;102:73-80.
11. Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, Jiménez D. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014;44:694-703.
12. Giannitsis E, Muller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M, Katus HA. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000;102:211-7.
13. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a metaanalysis. Circulation 2007;116:427-33.
14. Lankeit M, Friesen D, Aschoff J, Dellas C, Hasenfuss G, Katus H, et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010;31:1836-44.
15. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315.
16. Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, Meyer G. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008;29:1569-77.
17. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33:2001-6.
18. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low NT-proBNP levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107:1576-8.
19. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178:425-30.
20. Kostrubiec M, Pruszczyk P, Kaczynska A, Kucher N. Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. Clin Chim Acta 2007;382:124-8.
21. Glatz JF, Kleine AH, van Nieuwenhoven FA, Hermens WT, van Dieijen-Visser MP, van der Vusse GJ. Fatty-acidbinding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 1994;71:135-40.
22. Dellas C, Puls M, Lankeit M, Schafer K, Cuny M, Berner M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol 2010;55:2150-7.
23. Lauque D, Maupas-Schwalm F, Bounes V, Juchet H, Bongard V, Roshdy A, et al. Predictive value of the hearttype fatty acid-binding protein and the Pulmonary Embolism Severity Index in patients with acute pulmonary embolism in the emergency department. Acad Emerg Med 2014;21:1143-50.
24. Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008;177:1018-25.
25. Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J AmColl Cardiol 2011;58:1057-67.
26. Pedowska-Włoszek J, Kostrubiec M, Kurnicka K, Ciurzynski M, Palczewski P, Pruszczyk P. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism. Thromb Res 2013;132:506-10.
27. Liebetrau C, Nef H, Szardien S, Dörr O, Willmer M, Voss S, et al. Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy. Clin Chem 2013;59:566-9.
28. Hellenkamp K, Schwung J, Rossmann H, Kaeberich A, Wachter R, Hasenfuß G, et al. Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin. Eur Respir J 2015;46:1701-10.
29. Kostrubiec M, Łabyk A, Pedowska-Włoszek J, Dzikowska-Diduch O, Wojciechowski A, Garlińska M, et al. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism. Heart 2012;98:1221e8.
30. Qin J, Liang H, Shi D, Dai J, Xu Z, Chen D, et al. A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. J Thromb Thrombolysis 2015;39:215-21.
31. Xiao J, Jing ZC, Ellinor PT, Liang D, Zhang H, Liu Y, et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism, J Transl Med 2011;9:159.
32. Zhou X, Wen W, Shan X, Qian J, Li H, Jiang T, et al. MiR-28-3p as a potential plasma marker in diagnosis of pulmonary embolism. Thromb Res 2016;138:91-5.
33. Kessler T, Erdmann J, Vilne B, Bruse P, Kurowski V, Diemert P, et al. Serum microRNA-1233 is a specific biomarker for diagnosing acute pulmonary embolism. J Transl Med 2016;14:120.
34. Bujak R, García-Álvarez A, Rupérez FJ, Nuño-Ayala M, García A, Ruiz-Cabello J, et al. Metabolomics reveals metabolite changes in acute pulmonary embolism. J Proteome Res 2014;13:805-16.
35. Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, Konstantinides S. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011;124:2716-24.
36. Hobohm L, Hellenkamp K, Hasenfuß G, Münzel T, Konstantinides S, Lankeit M. Comparison of risk assessment strategies for not-high-risk pulmonary embolism. Eur Respir J 2016;47:1170-8.
37. Lankeit M, Jiménez D, Kostrubiec M, Dellas C, Kuhnert K, Hasenfuß G, et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014;43:1669-77.
38. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-615.
39. Lankeit M, Gómez V, Wagner C, Aujesky D, Recio M, Briongos S, et al. A strategy combining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism. Chest 2012;141:916-22.
40. Muller-Bardorff M, Weidtmann B, Giannitsis E, Kurowski V, Katus HA. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002;48:673-5.
41. Vuilleumier N, Limacher A, Méan M, Choffat J, Lescuyer P, Bounameaux H, et al. Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-high-risk pulmonary embolism. J Intern Med 2015;277:707-16.
42. Vanni S, Viviani G, Baioni M, Pepe G, Nazerian P, Socci F, et al. Prognostic value of plasma lactate levels among patients with acute pulmonary embolism: the thrombo-embolism lactate outcome study. Ann Emerg Med 2013;61:330-8.